Literature DB >> 25258175

Mobile teledermatology helping patients control high-need acne: a randomized controlled trial.

J Frühauf1, S Kröck, F Quehenberger, D Kopera, R Fink-Puches, P Komericki, S Pucher, E Arzberger, R Hofmann-Wellenhof.   

Abstract

BACKGROUND: Acne is an important health issue with a major psychological impact in addition to the physical problems it causes.
OBJECTIVES: To investigate the superiority of mobile teledermatology in the care of patients with high-need facial acne in comparison to outpatient services with particular attention to treatment efficacy, safety, and patient compliance. Further, patient satisfaction with remote care was evaluated.
METHODS: Sixty-nine consecutive patients (f: 25, m: 44, median age: 19 years, range: 13-37 years) were randomly allocated to either the teleconsultation (TCA) or the outpatient consultation (OCA) arm of the trial to receive isotretinoin treatment in weight and severity-dependent dosages over 24 weeks. Acne grading was performed by one examiner using the Global Acne Severity Scale (GEA) and the total lesion counting (TLC).
RESULTS: Due to noncompliance issues, 17 of 69 (24.6%) patients were excluded from the study, of who 10 had been assigned to the TCA (10/34; 29.4%) and 7 to the OCA (7/35; 20%). Both, in the TCA (GEA-score: ∆ = 2.25; TLC: ∆ = 89.08) and in the OCA (GEA-score: ∆ = 2.0; TLC: ∆ = 91.21) excellent and almost equivalent therapeutic outcomes were achieved. In the TCA, however, less patients experienced adverse reactions (P = 0.55). Even though additional live supervision would have been appreciated in some teledermatology cases, patients were satisfied with the mobile service and no consultation request was created.
CONCLUSION: Mobile teledermatology is an efficient, safe and well-accepted tool among patients with high-need acne constituting at least a valuable adjunct to outpatient care services. Further larger studies would be useful to confirm our findings.
© 2014 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25258175     DOI: 10.1111/jdv.12723

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

1.  Patient and Provider Satisfaction with Teledermatology.

Authors:  Richard Marchell; Craig Locatis; Gene Burgess; Richard Maisiak; Wei-Li Liu; Michael Ackerman
Journal:  Telemed J E Health       Date:  2017-04-04       Impact factor: 3.536

2.  Using Network Oriented Research Assistant (NORA) Technology to Compare Digital Photographic With In-Person Assessment of Acne Vulgaris.

Authors:  Hannah M Singer; Timothy Almazan; Noah Craft; Consuelo V David; Samantha Eells; Crisel Erfe; Cynthia Lazzaro; Kathy Nguyen; Katy Preciado; Belinda Tan; Vishal A Patel
Journal:  JAMA Dermatol       Date:  2018-02-01       Impact factor: 10.282

3.  Definitions, survey methods, and findings of patient satisfaction studies in teledermatology: a systematic review.

Authors:  Edward Hadeler; Howard Gitlow; Keyvan Nouri
Journal:  Arch Dermatol Res       Date:  2020-07-28       Impact factor: 3.017

4.  Recent trends in teledermatology and teledermoscopy.

Authors:  Katie J Lee; Anna Finnane; H Peter Soyer
Journal:  Dermatol Pract Concept       Date:  2018-07-31

5.  Evaluating healthcare practitioners' views on store-and-forward teledermoscopy services for the diagnosis of skin cancer.

Authors:  Monika Janda; Caitlin Horsham; Uyen Koh; Nicole Gillespie; Dimitrios Vagenas; Lois J Loescher; Clara Curiel-Lewandrowski; Rainer Hofmann-Wellenhof; H Peter Soyer
Journal:  Digit Health       Date:  2019-02-06

Review 6.  Teledermatology: current indications and considerations for future use.

Authors:  Jacob Beer; Edward Hadeler; Alejo Calume; Howard Gitlow; Keyvan Nouri
Journal:  Arch Dermatol Res       Date:  2020-10-19       Impact factor: 3.017

Review 7.  Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications.

Authors:  Claudio Marasca; Maria Carmela Annunziata; Elisa Camela; Adriana Di Guida; Luigi Fornaro; Matteo Megna; Maddalena Napolitano; Cataldo Patruno; Luca Potestio; Gabriella Fabbrocini
Journal:  J Clin Med       Date:  2022-03-10       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.